Skip to Content


National Cancer Institute; Notice of Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Date: July 29, 2003.

Time: 12 p.m. to 2 p.m.

Agenda: Update on NCI/DCLG Advocacy Survey; Consumer Advocates in Research and Related Activities update; preparation for September 24, 2003 face-to-face DCLG meeting; update on Clinical Trials project; and President's Cancer Panel survivorship initiative.

Place: National Institutes of Health, 6116 Executive Boulevard, Rm. 220, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Nancy Caliman, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institute, 6116 Executive Boulevard, Suite 220, MSC8324, Bethesda, MD 20892, (301) 496-0307,

This notice is being published less than 15 days prior to the meeting date to review the results of the NCI/DCLG Advocacy Survey and prepare for the September meeting. These results are critical to the future of the DCLG. Information is also available on the Institute's/Center's home page:​advisory/​dclg/​dclg.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Start Signature

Dated: July 8, 2003.

Anna P. Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. 03-17792 Filed 7-14-03; 8:45 am]